Dendreon attracts $45 million infusion
16th Nov 2006, 23:42 GMT
The Seattle company, the only local biotech with a drug currently awaiting Food and Drug Administration approval, sold 9.9 million shares of stock at about $4.55 a share.
Latest news from The Seattle Times: Horse racing:
- "Borat": The cheap shot heard 'round the world
- WaMu will pay $47 million to settle lawsuit
- Dendreon completes FDA filing for prostate-cancer drug
- S. Korea balks at U.S. pressure on sanctioning North
- Bush leads ceremony launching construction of King memorial
- Looking ahead in business
- From marigolds to mariachis at Xoxocotlan funerals
- Failing road closed; no auto access to 200 homes
- Virginia State Police swap "10-4" for "message understood"
- Toilet evidence links Dead Sea Scrolls to sect